Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.
Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.
One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.
Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.
Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.
Artelo Biosciences (Nasdaq: ARTL) announced advancements in its clinical programs with the CAReS Study for ART27.13, targeting cancer-related anorexia, progressing to a fourth cohort due to its well-tolerated safety profile. The company also reported a net loss of $2.4 million for Q2 2022 and a cash balance of $21.3 million, expected to fund operations into 2023. A 15-for-1 reverse stock split will take effect on August 10, 2022, aimed at enhancing stock marketability and compliance with Nasdaq requirements.
Artelo Biosciences (Nasdaq: ARTL) has initiated the fourth cohort at a 650-microgram dose in its Cancer Appetite Recovery Study (CAReS) for ART27.13, following successful completion of the first three cohorts. The safety review committee reported that ART27.13 was well-tolerated, with no serious adverse events linked to the drug. The Phase 1b trial will help determine the optimal dose before transitioning to a Phase 2a study. ART27.13 targets cannabinoid receptors to address cancer-related anorexia, tapping into a market exceeding $2 billion annually.
Artelo Biosciences (Nasdaq: ARTL) recently presented research at the ICRS Symposium highlighting the effectiveness of its lead compound, ART26.12, in managing chemotherapy-induced pain. Professor Saoirse O’Sullivan reported that ART26.12 demonstrated significant effectiveness in preventing and treating pain sensitivity without sedation, while also mitigating weight loss linked to chemotherapy. The company aims to pursue FDA consultations for ART26.12’s further development. This research opens potential pathways for addressing Chemotherapy-Induced Peripheral Neuropathy, a condition without approved therapies.
Artelo Biosciences (Nasdaq: ARTL) announced that Professor Saoirse O’Sullivan will present pre-clinical data on ART26.12, a fatty acid binding protein 5 inhibitor, at the International Cannabinoid Research Society Symposium on June 26, 2022. Gregory D. Gorgas, the company's CEO, expressed enthusiasm about sharing findings related to advancements in cancer treatment. Additionally, the William A. Devane Young Investigator of the Year Award will be presented at the event, recognizing significant contributions to cannabinoid research.
Artelo Biosciences (NASDAQ: ARTL) announced that CEO Gregory D. Gorgas will present at the LD Micro conference on June 7, 2022, at 2:30 PM PT. The event, held at Four Seasons Westlake Village, California, will feature live webcasting and replays available on their site. Artelo specializes in developing therapeutics targeting lipid-signaling pathways, addressing conditions like anorexia, cancer, PTSD, pain, and inflammation. The company emphasizes collaboration with experts and a focus on high-impact therapies.
Artelo Biosciences (NASDAQ: ARTL) announced that CEO Gregory D. Gorgas will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. Gorgas is scheduled for an in-person presentation on May 24, 2022, at 5:00 p.m. ET. The event will provide both virtual and in-person participation options, and the presentation will be webcast live, with a replay available. Artelo specializes in developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system.
Artelo Biosciences (NASDAQ:ARLT) will present at the MicroCap Rodeo Spring Into Action - Best Ideas Virtual Investor Conference, scheduled from May 16-20, 2022. CEO Gregory D. Gorgas will speak on May 16, 2022, at 2:00 p.m. ET, with a live webcast available for replay. Artelo focuses on developing therapeutics that modulate lipid-signaling pathways, targeting conditions like cancer and PTSD. Qualified investors can schedule one-on-one meetings for further discussions. For more details, visit www.artelobio.com.
Artelo Biosciences (Nasdaq: ARTL) reported financial and operational results for Q1 2022, maintaining approximately $23.5 million in cash and investments, expected to support operations into late 2023. The net loss increased to $2.0 million or $0.05 per share, compared to $1.7 million or $0.09 per share in Q1 2021. The company anticipates results from the Phase 1b CAReS trial concerning ART27.13, aimed at treating cancer-related anorexia, in Q3 2022. Ongoing collaborations and positive pre-clinical data were highlighted, with a focus on addressing cancer anorexia cachexia syndrome.
Artelo Biosciences (Nasdaq: ARTL) announced promising pre-clinical results for ART27.13, indicating its potential in treating cancer-related muscle degeneration (cachexia). Research from Trinity College Dublin reveals that ART27.13 acts as a G-Protein Coupled Receptor agonist, targeting both CB1 and CB2 receptors. This could address significant patient needs, as cachexia impacts up to 80% of advanced cancer patients. ART27.13 is currently involved in the ongoing CAReS study for cancer appetite recovery.
Artelo Biosciences (Nasdaq: ARTL) announced a collaboration with Dr. Richard K. Porter at Trinity College Dublin to explore the role of fatty acid binding protein (FABP) inhibition in cancer treatment. This partnership aims to enhance understanding of FABP inhibitors and their potential for various tumors, which could lead to new treatments targeting unmet medical needs. The research is expected to yield multiple data readouts over the next year, reinforcing ART26.12's promise in oncology while expanding its compound library for targeted therapies.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What does Artelo Biosciences do?
Where is Artelo Biosciences headquartered?
What are the main therapeutic areas Artelo Biosciences focuses on?
What is ART12.11?
What is ART26.12?
What is ART27.13?
What recent achievement has ART12.11 demonstrated?
What progress has been made in the ART26.12 program?
Who leads Artelo Biosciences?
Where can I find more information about Artelo Biosciences?
